New Zealand Pharmaceuticals & Healthcare Report

Published 22 April 2015

  • 90 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
New Zealand Pharmaceuticals & Healthcare Report

BMI View : New Zealand will maintain a low-risk and business friendly operating environment, characterised by stable governance and a consistent regulatory agenda . E fforts to increase the uptake of generic s and biosimilars will be hampered by the branded drug bias of an aging population who demand access to rising volumes of innovative pharmaceuticals. However , the conversion of these conditions into growth for drugmakers will increasingly be frustrated by the constraints placed upon public health expenditure by demographic trends . While New Zealand will maintain an above OECD average rate of health insurance over the forecast period, as it ages, the country's base of working age contributors will continue a steady decline. This will mount increasing pressure on PHARMAC's already oversubscribed budget and as such , with a major spending increase or restructuring of social services unlikely, drugmakers will continue to perceive low rewards .

Headline Expenditure Forecasts

  • Pharmaceuticals : NZD1.45bn (USD1.20bn) in 2014 to NZD1.48bn (USD1.07bn) in 2015; 2% in local currency terms and -11.4% in US dollar terms. Forecast revised downwards from last quarter.

  • Healthcare: NZD22.57bn (USD18.72bn) in 2014 to NZD23.10bn (USD16.63bn) in 2015; 2.3% in local currency terms and -11.1% in US dollar terms. Forecast revised downwards from last quarter.

Risk/Reward Index

New Zealand's scores 53.1 out of 100, unchanged from Q215. This score is supported by its stable economic and political institutions and developed regulatory regime. However, the small size and modest growth of this market cause New Zealand to markedly underperform in the industry rewards segment relative to the region. As such, the country remains ranked ninth out of the 19 markets in the Asia Pacific Risk/Reward Index matrix.

Key Trends & Developments

  • In March 2015, the governments of New Zealand and China entered discussions to expand their bilateral free trade...

Table of Contents

BMI Industry View
7
SWOT
9
SWOT
9
Political
10
Economic
11
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2011-2019)
16
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
19
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
21
OTC Medicine Market Forecast
21
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
26
Pharmaceutical Trade Forecast
26
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2013-2019)
28
Key Risks To BMI's Forecast Scenario
28
Macroeconomic Forecasts
30
Economic Analysis
30
Industry Risk Reward Ratings
34
Asia Pacific Risk/Reward Index
34
New Zealand Risk/Reward Index
40
Rewards
40
Risks
40
Market Overview
42
Industry Trends And Developments
43
Epidemiology
43
Healthcare Sector
45
Infrastructure
46
Table: Healthcare Resources (New Zealand 2009-2014)
46
Table: Healthcare Activity (New Zealand 2009-2014)
46
Table: Healthcare Personnel (New Zealand 2009-2014)
47
Distribution Channels
47
Table: Pharmacybrands Stores By Company & Region, 2010
49
Research And Development
50
Clinical Trials Sector
50
Regulatory Development
53
Regulatory Regime
53
Intellectual Property Regime
53
Pricing & Reimbursement
54
Table: Leading Therapeutic Groups By PHARMAC Expenditure (NZDmn), 2005-2010
59
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
60
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
61
Recent Regulatory Developments
61
Competitive Landscape
63
Company Profile
64
Southern Cross Healthcare Group
64
Douglas Pharmaceuticals
70
New Zealand Pharmaceuticals
73
Pfizer New Zealand
76
Demographic Forecast
78
Table: Population Headline Indicators (New Zealand 1990-2025)
79
Table: Key Population Ratios (New Zealand 1990-2025)
79
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025)
80
Table: Population By Age Group (New Zealand 1990-2025)
80
Table: Population By Age Group % (New Zealand 1990-2025)
81
Glossary
83
Methodology
85
Pharmaceutical Expenditure Forecast Model
85
Healthcare Expenditure Forecast Model
85
Notes On Methodology
86
Risk/Reward Index Methodology
87
Index Overview
88
Table: Pharmaceutical Risk/Reward Index Indicators
88
Indicator Weightings
89

The New Zealand Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's New Zealand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the New Zealand pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for New Zealand, to test other views - a key input for successful budgeting and strategic business planning in the New Zealand pharmaceutical and healthcare market.
  • Target business opportunities and risks in the New Zealand pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in New Zealand.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc